New Treatment Options for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Community

CME: 0.5

Target Audience

The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.

Statement of Need/Program Overview

The symptoms of paroxysmal nocturnal hemoglobinuria (PNH) vary between patients which makes recognition of PNH difficult and creates significant diagnostic delays that take a toll on patients. The changing treatment landscape also challenges clinicians to stay up to date with new therapies while helping patients navigate a difficult disease course.

As part of the “Annual Rare Cancers and Blood Disorders Series,” join a renowned hematologist for this educational activity on the importance of an early diagnosis of PNH to ensure prompt and effective treatment. This session will review the clinical evidence on complement inhibitor therapies for PNH and explore strategies to integrate these treatments into patient care and manage treatment‐associated adverse events. Clinicians will also learn how to engage with patients to improve quality of life, find support, and share their experiences.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss the heterogenous manifestations of PNH and the need for timely recognition of symptoms for early and accurate diagnosis of PNH
  • Evaluate latest efficacy and safety data on current and emerging complement inhibitory therapies for children and adults with symptomatic PNH.
  • Integrate complement inhibitory therapies into the management of patients diagnosed with PNH
  • Discuss how Global PNH registry can improve future determination of disease course and impact of treatment

Post a comment to this article